• Conference Proceeding

Perinatal outcomes in pregnant women exposed to omalizumab: Interim results from a prospective, observational study

Citation

Namazy, J. A., Rahmaoui, A., Cabana, M. D., Scheuerle, A. E., Thorp, J. M., Carrigan, G., & Andrews, E. B. (2015). Perinatal outcomes in pregnant women exposed to omalizumab: Interim results from a prospective, observational study. In [135], p. AB1. .

Abstract

Rationale
Data regarding maternal and fetal outcomes for many asthma medications are insufficient.

Methods
EXPECT is an ongoing prospective, observational study of pregnant women exposed to ?1 dose of omalizumab within 8 weeks prior to conception or at any time during pregnancy. Data on mother and pregnancy/infant are collected at enrollment, each trimester of pregnancy, pregnancy outcome, and up to 18 months post-delivery. Maternal asthma severity is assessed by mother’s health provider. Data collected: rates of live births, spontaneous abortions, elective terminations, stillbirths, birth weight, gestational age, and congenital anomalies. Data are from an annual cumulative summary including September 29, 2006 -November 30, 2013.

Results
Of 207 prospectively enrolled pregnancies, outcomes from 186 pregnancies were reported. Asthma severity was available for 164 women: mild (4/164, 2.4%), moderate (55/164, 33.5%), severe (105/164, 64.0%). There were 174 live births of 178 infants (4 twin pairs), 8 spontaneous abortions, 2 fetal deaths/stillbirths and 2 elective terminations. Of 170 singleton infants, 24 (14.1%) were born prematurely (
Conclusions
Given the small sample size and severity of maternal asthma, these pregnancy outcomes are not inconsistent with previous observations.